HK Stock Market Move | PEGBIO CO-B-50(02565) rises more than 13% CR059 receives acceptance and is selected for oral discussion in the EASD 2026.

PEGBIO CO-B-50 (02565) rose more than 13%, as of the time of writing, it rose by 9.8%, reaching 8.75 Hong Kong dollars with a turnover of 1.08 billion Hong Kong dollars. On the news side, on June 1st, PEGBIO CO-B-50 announced that the research results of the group's independently developed cyclic RNA encoding GLP-1 analog CR059 have been accepted by the 62nd Annual Meeting of the European Association for the Study of Diabetes ("EASD 2026"), and have been selected for oral presentation. Following the previous selection of CR059 related research results for the American Diabetes Association Annual Meeting's Late-Breaking Abstract, this time it has been accepted by EASD 2026 for oral presentation, marking the continuous high attention and recognition of CR059 and the group's cyclic RNA technology platform at the two major international academic conferences in the field of diabetes and metabolic diseases. The company believes that the core innovative value of CR059 lies in its potential to break through the existing treatment model of GLP-1 drugs mainly administered weekly, further expanding towards ultra-long-term treatment intervals of monthly or even quarterly injections. If successful in clinical translation, this technological pathway is expected to significantly reduce the long-term medication burden of patients with chronic metabolic diseases, improve treatment compliance and long-term management efficiency, and provide a new generation of solutions distinct from existing peptide drugs for obesity, type 2 diabetes, and related metabolic diseases.